Circulating Tumor Dna

Healio spoke with Eleonora Teplinsky, MD, about research on circulating tumor DNA in breast cancer.

Circulating tumor DNA genotyping before tissue diagnosis of suspected advanced non-small cell lung cancer resulted in significantly shorter median time to treatment compared with standard tissue testing, study results showed.

CHICAGO — Negative circulating tumor DNA status contributed to a PFS benefit for patients with previously untreated diffuse large B-cell lymphoma, according to research presented at ASCO Annual Meeting.

In this video, Thomas Marron, MD, PhD, discussed data he presented on patients with liver cancer treated with neoadjuvant cemiplimab (Libtayo, Regeneron) at American Association for Cancer Research Annual Meeting.

Circulating tumor DNA testing appeared to identify risk for recurrence among patients with stage II to stage IV colorectal cancer, according to study results published in Nature Medicine.

Liquid biopsy effectively predicted survival outcomes among a cohort of patients with various metastatic cancer types, according to study results published in Annals of Oncology.

Within the past decade, data have emerged indicating an effective role of circulating tumor DNA in identifying lung cancer at an early stage and in matching patients with appropriate treatments.

The potential for ctDNA-guided management to reduce adjuvant chemotherapy by half without compromising recurrence-free survival sparked interest on social media after a presentation at the ASCO Annual Meeting.

CHICAGO — Circulating tumor DNA analysis safely reduced adjuvant chemotherapy use without compromising recurrence-free survival among patients with stage II colon cancer, according to results of the randomized phase 2 DYNAMIC trial.

A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.